Profound Medical's Sonalleve Reaches 500 Procedures at PRO FAMILIA Hospital, Highlighting International Growth
Summary
Profound Medical announced a key milestone for its Sonalleve product, with a Polish hospital completing its 500th procedure, underscoring the therapy's growing international adoption for women's health.
Key Events
-
Sonalleve Reaches 500 Procedures at PRO FAMILIA Hospital
PRO FAMILIA Specialist Hospital in Rzeszów, Poland, completed its 500th Sonalleve® Procedure, an MRI-guided, incision-free therapy for gynecologic conditions.
-
Demonstrates Growing International Adoption
This milestone highlights increasing commercial interest and adoption of Sonalleve, with over 4,000 women treated globally across 10 operational devices in Europe, China, and Southeast Asia.
-
Expands Access to Non-Surgical Women's Health Care
The Sonalleve system provides a non-surgical alternative for treating conditions like uterine fibroids and adenomyosis, offering benefits like no incisions, no blood loss, and faster recovery.
Analysis
This 8-K reports a significant operational milestone for Profound Medical's Sonalleve product, with PRO FAMILIA Specialist Hospital completing its 500th procedure. This achievement, alongside over 4,000 total Sonalleve treatments globally, demonstrates increasing international adoption and commercial interest in the non-surgical therapy for women's health conditions. While the company's primary focus remains TULSA-PRO, the continued growth of Sonalleve contributes positively to the company's product portfolio and market presence.
At the time of this filing, PROF was trading at $6.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $247.5M. The 52-week trading range was $3.76 to $8.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.